Cyclodextrin-based host-guest complexes loaded with regorafenib for colorectal cancer treatment

Hongzhen Bai; Jianwei Wang; Chi Uyen Phan; Qi Chen; Xiurong Hu; Guoqiang Shao; Jun Zhou; Lihua Lai; Guping Tang

doi:10.1038/s41467-021-21071-0

Nature Communications (Feb 2021)

Cyclodextrin-based host-guest complexes loaded with regorafenib for colorectal cancer treatment

Hongzhen Bai,
Jianwei Wang,
Chi Uyen Phan,
Qi Chen,
Xiurong Hu,
Guoqiang Shao,
Jun Zhou,
Lihua Lai,
Guping Tang

Affiliations

Hongzhen Bai: Department of Chemistry, Zhejiang University
Jianwei Wang: Department of Chemistry, Zhejiang University
Chi Uyen Phan: Department of Chemistry, Zhejiang University
Qi Chen: Department of Chemistry, Zhejiang University
Xiurong Hu: Department of Chemistry, Zhejiang University
Guoqiang Shao: Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University
Jun Zhou: Department of Chemistry, Zhejiang University
Lihua Lai: Department of Pharmacology, School of Medicine, Zhejiang University
Guping Tang: Department of Chemistry, Zhejiang University

DOI: https://doi.org/10.1038/s41467-021-21071-0
Journal volume & issue: Vol. 12, no. 1
pp. 1 – 18

Abstract

Read online

Regorafenib is a multi-kinase inhibitor in use for the treatment of colorectal cancer (CRC). To improve drug pharmacokinetics and bioavailability, here the authors design mannose-modified cyclodextrin-based host-guest complexes loaded with Regorafenib, showing anti-tumor responses in preclinical models of CRC.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal